ClinicalTrials.gg
RecruitingNCT04365036Updated Mar 13, 2025

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

A Phase 3 interventional study of Toripalimab and Pegaspargase in NK/T Cell Lymphoma Nos, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphoma, T-Cell · Sun Yat-sen University.

Started
2020
the only one that year
Phase 3
2 of 11
1 open now
Registered
4th of 11
by date

Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, this one is the only one that started in 2020, is one of 2 in phase 3, and was the 4th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

6 of the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, or all of them as a file.
02

Study summary

The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)

03

Conditions studied

  • NK/T Cell Lymphoma Nos

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proved extranodal natural killer/T-cell lymphoma, nasal type;
  • newly diagnosed stage I/II patients;
  • at least one evaluable lesion;
  • PS 0-2;
  • 18-75 years; without other ;
  • proper functioning of the major organs.

Exclusion criteria

Exclusion Criteria:

  • hemophagocytic syndrome or aggressive NK cell leukemia;
  • involvement of central nervous system;
  • previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (estimated)

Study arms

  • Experimental
    toripalimab with P-GemOx

    Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.

    Drug: Toripalimab · Drug: Pegaspargase · Drug: Gemcitabine · Drug: Oxaliplatin · Radiation: Definitive intensity-modulated radiotherapy (IMRT)

  • Active comparator
    P-GemOx

    Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.

    Drug: Pegaspargase · Drug: Gemcitabine · Drug: Oxaliplatin · Radiation: Definitive intensity-modulated radiotherapy (IMRT)

Interventions

  • toripalimab 240mg, d1, intravenous drip

  • pegaspargase, 2000U/m2, d1, intravenous drip

  • gemcitabine, 1000mg/m2, d1,d8, intravenous drip

  • oxaliplatin, 130mg/m2, d1, intravenous drip,

  • RadiationDefinitive intensity-modulated radiotherapy (IMRT)

    Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days

06

What researchers measure

Primary outcomes

  1. progression free survival (PFS)

    Time frame: 3 years

Secondary outcomes

  1. complete remission (CR) rate

    Time frame: From the start of treatment with the interventions until 6 months

  2. overall response rate (ORR)

    Time frame: From the start of treatment with the interventions until 6 months

  3. overall survival (OS)

    Time frame: 3 years

  4. recurrence-free survival (RFS)

    Time frame: 3 years

  5. event free survival (EFS)

    Time frame: 3 years

  6. disease-free survival (DFS)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Dec 2028, 103 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 28, 2020
StartActual
May 3, 2020
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04365036
Responsible party
Qingqing Cai (Chief physician, Sun Yat-sen University) — Principal investigator
First posted
Apr 28, 2020
Start date
May 3, 2020
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 13, 2025

Study contacts

Qingqing Cai, MD
Contact
caiqq@sysucc.org.cn
0086-20-87342823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Toripalimab

Start the discussion